Olorigliflozin

Olorigliflozin
Clinical data
Other names	Rongliflozin; DJT1116PG
Identifiers
	IUPAC name (1R,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-[(1R)-1-hydroxyethyl]-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol;
CAS Number	2035989-50-3;
PubChem CID	122660464;
ChemSpider	129498851;
UNII	6FP3NST6ZQ;
ChEMBL	ChEMBL5314927;
Chemical and physical data
Formula	C23H27ClO7
Molar mass	450.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)[C@@H](C)O)O)O)O)Cl;
	InChI InChI=1S/C23H27ClO7/c1-3-29-17-7-4-14(5-8-17)10-15-11-16(6-9-18(15)24)23-21(28)19(26)20(27)22(31-23,12-30-23)13(2)25/h4-9,11,13,19-21,25-28H,3,10,12H2,1-2H3/t13-,19+,20+,21-,22-,23+/m1/s1; Key:KODGTDKHPNYCCJ-YWRILDCISA-N;

Olorigliflozin, also known as rongliflozin, is an investigational new drug that is being evaluated by HEC Pharm for the treatment of type 2 diabetes mellitus.^[1] It is a sodium-glucose transporter 2 inhibitor.^[1]^[2]^[3]^[4]^[5]^[6]

References

1 2 "Olorigliflozin - HEC Pharm". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.
↑ Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.
↑ Chen M, Cao X, An K, Wang Y, Yan Q, Men Y, et al. (December 2025). "Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial". Clinical Pharmacokinetics. 64 (12): 1897–1907. doi:10.1007/s40262-025-01584-3. PMID 41105382.
↑ He YF, Ma JH, Wang HF, Zeng JE, Li ZB, Pan TR, et al. (June 2026). "[Efficacy and safety of olorigliflozin monotherapy in patients with type 2 diabetes mellitus with poor glycemic control on diet and exercise interventions]". Zhonghua Yi Xue Za Zhi. 106 (21): 2128–2137. doi:10.3760/cma.j.cn112137-20260331-00864. PMID 42252238.
↑ He YF, Cheng ZF, Bian F, Li S, Li LP, Shang JJ, et al. (June 2026). "[Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy]". Zhonghua Yi Xue Za Zhi. 106 (21): 2138–2149. doi:10.3760/cma.j.cn112137-20260331-00868. PMID 42252239.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[AdisInsight_olorigliflozin-1] 1 2 "Olorigliflozin - HEC Pharm". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.

[Zhang_2020a-2] Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.

[Zhang_2020b-3] Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.

[Chen_2025-4] Chen M, Cao X, An K, Wang Y, Yan Q, Men Y, et al. (December 2025). "Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial". Clinical Pharmacokinetics. 64 (12): 1897–1907. doi:10.1007/s40262-025-01584-3. PMID 41105382.

[He_2026_a-5] He YF, Ma JH, Wang HF, Zeng JE, Li ZB, Pan TR, et al. (June 2026). "[Efficacy and safety of olorigliflozin monotherapy in patients with type 2 diabetes mellitus with poor glycemic control on diet and exercise interventions]". Zhonghua Yi Xue Za Zhi. 106 (21): 2128–2137. doi:10.3760/cma.j.cn112137-20260331-00864. PMID 42252238.

[He_2026_b-6] He YF, Cheng ZF, Bian F, Li S, Li LP, Shang JJ, et al. (June 2026). "[Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy]". Zhonghua Yi Xue Za Zhi. 106 (21): 2138–2149. doi:10.3760/cma.j.cn112137-20260331-00868. PMID 42252239.

[1]

[2]

[3]

[4]

[5]

[6]

v t e Sodium-glucose transporter modulators
SGLT1Tooltip Sodium/glucose cotransporter 1	Inhibitors: Phloretin Phlorizin T-1095 T-1095A
SGLT2Tooltip Sodium/glucose cotransporter 2	Inhibitors: Atigliflozin Bexagliflozin Canagliflozin Dapagliflozin Empagliflozin Enavogliflozin Ertugliflozin Henagliflozin Ipragliflozin Janagliflozin Licogliflozin Luseogliflozin Mizagliflozin Olorigliflozin Phloretin Phlorizin Remogliflozin Sergliflozin T-1095 T-1095A Tofogliflozin Velagliflozin Antisense oligonucleotides: ISIS-388626
SGLT1Tooltip Sodium/glucose cotransporter 1 & SGLT2Tooltip Sodium/glucose cotransporter 2	Inhibitors: Sotagliflozin
See also: Receptor/signaling modulators

This page was redesigned at the edge.

References